AlveoGene announced that it has been granted a RPDD by the US FDA for AVG-002, its novel inhaled gene therapy for lethal neonatal SP-B deficiency.
[AlveoGene]
Home Newsletters Cell Therapy News AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, Its...
